Cargando…
Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System
In situ forming nanovesicular systems (IFNs) were prepared and optimized to improve Rosuvastatin calcium (RC) oral bioavailability through increasing its solubility and dissolution rate. The IFN was composed of Tween(®) 80 (T80), cetyl alcohol (CA), in addition to mannitol or Aerosil 200. A single s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631901/ https://www.ncbi.nlm.nih.gov/pubmed/31212660 http://dx.doi.org/10.3390/pharmaceutics11060275 |
_version_ | 1783435627145986048 |
---|---|
author | Elsayed, Ibrahim El-Dahmy, Rania Moataz Elshafeey, Ahmed Hassen Abd El Gawad, Nabaweya Abdelaziz El Gazayerly, Omaima Naim |
author_facet | Elsayed, Ibrahim El-Dahmy, Rania Moataz Elshafeey, Ahmed Hassen Abd El Gawad, Nabaweya Abdelaziz El Gazayerly, Omaima Naim |
author_sort | Elsayed, Ibrahim |
collection | PubMed |
description | In situ forming nanovesicular systems (IFNs) were prepared and optimized to improve Rosuvastatin calcium (RC) oral bioavailability through increasing its solubility and dissolution rate. The IFN was composed of Tween(®) 80 (T80), cetyl alcohol (CA), in addition to mannitol or Aerosil 200. A single simple step was adopted for preparation, then the prepared formulations were investigated by analyzing their particle size (PS), polydispersity index (PDI), Zeta potential (ZP), entrapment efficiency (EE), and flowability properties. D-optimal design was applied to choose the optimized formulations. The maximum desirability values were 0.754 and 0.478 for the optimized formulations containing 0.05 g CA, 0.18 g T80, and 0.5 g mannitol (OFM) or Aerosil (OFA), respectively. In vitro drug release from the optimized formulations showed a significantly faster dissolution rate when compared to the market product. In vivo performance of the optimized formulations in rabbits was investigated after filling them into enteric-coated capsules. Ultimately, OFA formulation achieved a 3 times increase in RC oral bioavailability in comparison with the market product, supporting the hypothesis of considering IFNs as promising nanocarriers able to boost the bioavailability of BCS class II drugs. |
format | Online Article Text |
id | pubmed-6631901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66319012019-08-19 Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System Elsayed, Ibrahim El-Dahmy, Rania Moataz Elshafeey, Ahmed Hassen Abd El Gawad, Nabaweya Abdelaziz El Gazayerly, Omaima Naim Pharmaceutics Article In situ forming nanovesicular systems (IFNs) were prepared and optimized to improve Rosuvastatin calcium (RC) oral bioavailability through increasing its solubility and dissolution rate. The IFN was composed of Tween(®) 80 (T80), cetyl alcohol (CA), in addition to mannitol or Aerosil 200. A single simple step was adopted for preparation, then the prepared formulations were investigated by analyzing their particle size (PS), polydispersity index (PDI), Zeta potential (ZP), entrapment efficiency (EE), and flowability properties. D-optimal design was applied to choose the optimized formulations. The maximum desirability values were 0.754 and 0.478 for the optimized formulations containing 0.05 g CA, 0.18 g T80, and 0.5 g mannitol (OFM) or Aerosil (OFA), respectively. In vitro drug release from the optimized formulations showed a significantly faster dissolution rate when compared to the market product. In vivo performance of the optimized formulations in rabbits was investigated after filling them into enteric-coated capsules. Ultimately, OFA formulation achieved a 3 times increase in RC oral bioavailability in comparison with the market product, supporting the hypothesis of considering IFNs as promising nanocarriers able to boost the bioavailability of BCS class II drugs. MDPI 2019-06-11 /pmc/articles/PMC6631901/ /pubmed/31212660 http://dx.doi.org/10.3390/pharmaceutics11060275 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Elsayed, Ibrahim El-Dahmy, Rania Moataz Elshafeey, Ahmed Hassen Abd El Gawad, Nabaweya Abdelaziz El Gazayerly, Omaima Naim Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System |
title | Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System |
title_full | Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System |
title_fullStr | Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System |
title_full_unstemmed | Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System |
title_short | Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System |
title_sort | tripling the bioavailability of rosuvastatin calcium through development and optimization of an in-situ forming nanovesicular system |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631901/ https://www.ncbi.nlm.nih.gov/pubmed/31212660 http://dx.doi.org/10.3390/pharmaceutics11060275 |
work_keys_str_mv | AT elsayedibrahim triplingthebioavailabilityofrosuvastatincalciumthroughdevelopmentandoptimizationofaninsituformingnanovesicularsystem AT eldahmyraniamoataz triplingthebioavailabilityofrosuvastatincalciumthroughdevelopmentandoptimizationofaninsituformingnanovesicularsystem AT elshafeeyahmedhassen triplingthebioavailabilityofrosuvastatincalciumthroughdevelopmentandoptimizationofaninsituformingnanovesicularsystem AT abdelgawadnabaweyaabdelaziz triplingthebioavailabilityofrosuvastatincalciumthroughdevelopmentandoptimizationofaninsituformingnanovesicularsystem AT elgazayerlyomaimanaim triplingthebioavailabilityofrosuvastatincalciumthroughdevelopmentandoptimizationofaninsituformingnanovesicularsystem |